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Aims of this review article 
This review article aims to explain the important issues that Data Safety Monitoring Boards 
(DSMB) face when considering early termination of a trial (see Table of Contents) and is 
specifically addressed to the needs of clinical and research cardiologists. We give an insight 
into the overall background and then focus on the three principal reasons for stopping trials.  
The statistical essentials are also addressed to familiarize clinicians with the key principles. 
The topic is further highlighted by numerous examples from lipid trials and antithrombotic 
trials. 
This is followed by an overview of regulatory aspects, including an insight into industry-
investigator interactions. 
To conclude, we summarize the key elements that are the basis for a decision to stop a 
randomized clinical trial. 
 
Background and challenge  
In a recent article published in this Journal 1, we have reviewed the selection of endpoints for 
RCTs. With the accumulation of recorded endpoints, it is ethically appropriate in every trial to 
perform interim analyses in order to ensure the safety of investigational treatments. For this 
purpose, data safety monitoring boards (DSMBs) are a cornerstone of contemporary trials. 
The aim of the regular meetings of DSMBs is to protect trial participants from harm. Three 
important challenges may occur that necessitate premature stopping of a trial: overwhelming 
efficacy, futility, or harm (Figure 1). 
A different kind of challenge is the disadvantage of stopping a trial. A huge investment of 
effort is partly lost in that less evidence is gained when the preplanned size and duration of 
the trial is reduced. 
 
Responsibilities of the DSMB members    
 
There are many issues to consider when conducting and monitoring a randomized clinical 
trial. The clinical trial is undertaken to fill gaps in knowledge regarding specific alternative 
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options. With the introduction into a trial of a proposed new treatment (drug, device or 
strategy), there is an important responsibility on the DSMB and trial management to consider 
all information being collected, in timely fashion, with predefined criteria and interim analysis 
plans, to be done by an independent statistician not otherwise involved in the trial.  
To reinforce safety concerns, all investigators and all local and national ethics review 
committees periodically receive (in blinded fashion) a listing of suspected unexpected serious 
adverse reactions (SUSARS). People involved in the trial may raise issues and refer 
suspicions of harm to trial management and the DSMB, who will then examine in more detail 
unexpected signals emerging during the trial. 
 
The DSMB charter  
The DSMB charter 2, drawn up at the outset of the trial, should define monitoring procedures 
including plans for interim or ongoing analytic data. Reports of interim results should be 
presented to the DSMB in semi-blinded fashion (A vs B). It is then common practice for the 
DSMB to request the unblinding of the treatment arms.  Different thresholds for harm can be 
applied according to the investigational treatment like in the case where a new treatment 
may potentially cause a distinct benefit or distinct side effect, as with antithrombotic agents, 
where bleeding is a potential safety issue. But the general principle is that a DSMB functions 
better when it is fully aware of the unblinded interim evidence. 
 
Reasons for early stopping of an RCT 
With the scope of protecting trial participants from possible harm and not prolonging a trial 
when the answer is clear, there are threee main reasons for stopping a trial early. 
 
Efficacy 
First, upon interim analysis, clear evidence can arise that the new treatment appears 
superior. In this situation, it is unethical to subject patients of the control group to an inferior 
treatment. However a trial should only be stopped because of overwhelming evidence of 
efficacy. Again, it is important to consider specific endpoints that show such efficacy paying 
particular attention to the pre-defined primary endpoint, which is often a composite of major 
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revascularization rates, or surrogate outcomes. In this case, if the prognosis of randomized 
subjects is not affected, there are no reasons for requesting premature discontinuation. 
 
Futility  
Second, the accumulating interim data in a trial may reveal a lack of efficacy, i.e. it looks like 
there will not be a positive result in terms of a significant difference in endpoints between 
treatment arms, even if the trial continues to its preplanned end. One can argue that in the 
interest of participants, the trial should be stopped because they should not be subject to 
unnecessary investigations. Moreover, for the sponsor stopping is advantageous in this 
setting because of cost savings. 
The paramount level of decision is the predefined primary endpoint of the study. If it is a 
composite endpoint, then decision-making can be tricky. For instance, if a 3-point MACE 
endpoint (Major Acute Cardiovascular Event: death, MI or stroke) does not improve, but 
stroke alone appears to do so, then there may be a case to continue the trial. Also, if clear 
evidence of lack of efficacy has key implications for future clinical practice, then stopping 
early for futility may be inappropriate. 
 
Safety 
Third, and more serious, there can be a signal of harm. If there is the impression that an 
endpoint increases in the new treatment arm, it is important to distinguish between hard and 
soft endpoints 2, with increased all-cause mortality representing the hardest indication to stop 
a trial, followed by disease specific mortality (i.e. cardiovascular) or cardiovascular morbidity 
(MI, stroke). Next, an important distinction is whether evidence of harm is to be expected 
(e.g. bleeding events). This aspect is a challenge for a DSMB to act wisely, requiring a 
judgement based on the totality of evidence that the new treatment is harm. Potential 
evidence of harm may provoke the needs for more frequent interim reports and DSMB 
meetings. 
 
Combined reasons for trial stopping 
In some instances, a combination of reasons to stop appears appropriate. One example is 
the HPS2Thrive (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of 






/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaa126/5949105 by St G
eorge's U





laropiprant on the background of statin-ezetimibe therapy was tested against statin alone. As 
to efficacy endpoints, futility became evident, and, in addition, cutaneous and 
gastrointestinal, diabetes incidence, and musculoskeletal side effects increased in the 
nicotinic acid arm. The decision to stop the trial was based on both these facts. 
A further unusual reason led to the premature stopping of the SPIRE 1 and 2 trials 4,5, 
respectively. The PCSK9 inhibitor bococizumab gave rise to neutralizing antibodies leading 
to a partial loss of efficacy. The manufacturer decided not to market the drug and thus 
stopped the two trials that were at different stages, and, consequently to discontinue the 
whole bococizumab program. 
 
Examples from lipid trials 
First evidence for a statin benefit in diabetes mellitus patients had risen from trials where 
diabetic patients constituted an important minority, like the HPS (Heart Protection Study) trial 
6,  but the main population (72.5%) was non-diabetic. Therefore, the CARDS (Collaborative 
Atorvastatin Diabetes Study) 7 study was initiated that included exclusively patients with 
diabetes. The duration of the trial was planned for 5 years. However, at interim analyses it 
was evident that the benefits of statin versus placebo were very marked. In order to not 
expose placebo-treated patients to an unacceptable risk, the trial was stopped prematurely 
after the second interim analysis showed a significant benefit with treatment. 
Another example is JUPITER (Justification for the Use of statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin) 8. In this primary prevention trial in patients with 
elevated hsCRP (≥2 mg/L or <2 mg/L) using rosuvastatin versus placebo, an early benefit 
emerged and led to a premature termination after a median follow-up of 1.9 years rather than 
the intended 5-year follow-up. This was justified by the observed reduction of hard endpoints, 
including all-cause mortality. However, later on, the termination was criticized and some 
experts pointed out that a lot of valuable information was lost by the premature termination of 
the trial. Interestingly, no increase in the rate of adverse effects was detected in an analysis 
of participants who continued to receive treatment for 4 or more years 9. 
After older studies in the pre-statin era had shown benefit for nicotinic acid to reduce 
cardiovascular events like in the CDP (Coronary Drug Project) 10 and HATS (HDL-
Atheroscloerosis Treatment Study) 11, mostly in monotherapy, the idea was to combine 
nicotinic acid to statins. Among new trials, ARBITER 6-HALTS (Arterial Biology for the 
Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment 
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combination of statins with nicotinic acid 12. By carotid ultrasound, it appeared that lesions 
were less fast progressing or even regressing. Because of this level of “efficacy”, the trial 
was prematurely terminated. The study, although a late breaking trial at the AHA meeting 
and published amendments in the NEJM, was criticized by the official AHA discussant, John 
Kastelein. The criticism was mainly that a surrogate endpoint and not a hard endpoint led to 
early stopping. Later on, large outcome studies with a comparable combination therapy like 
AIM-HIGH (The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High 
Triglycerides: Impact on Global Health Outcomes) 13 and HPS THRIVE (Heart Protection 
Study 2 – Treatment of HDL to Reduce the Incidence of Vascular Events) 3 failed to 
demonstrate benefit, proving that it can be misleading to stop a trial based on imaging 
results. 
The TRACE-RA (Atorvastatin for the Primary Prevention of Cardiovascular Events in 
Patients with Rheumatoid Arthritis) trial was designed to assess whether statin therapy is 
superior to placebo for the primary prevention of cardiovascular events (CVE) in rheumatoid 
arthritis patients who do not have an indication for statins based on their CV risk 14. The 
unexpectedly low CVE rate limited the statistical power to detect an effect during the planned 
5 years of follow-up and led to premature termination of the trial after a median of 2.5 years. 
In hindsight, the non-significant observed relative risk reduction was in line with the 
significant results from other larger statin RCTs suggesting that such premature stopping 
was not a wise decision. 
 
Examples from antithrombotic and anticoagulation trials 
In the field of antithrombotic and anticoagulant therapy, the AVERROES study compared the 
efficacy of the factor Xa inhibitor apixaban versus aspirin (then the standard of care) in 5599 
patients with atrial fibrillation and low risk for thromboembolic events 15. At the first planned 
interim analysis the DSMB, observed a treatment benefit in favor of apixaban for the primary 
outcome that exceeded 4 SD. After a confirmatory analysis 3 months later (p value 
0.000002, z=4.76) the DSMB recommended stopping the study with a shorter than planned 
mean follow-up time of 1.1 years. Importantly, there was no evidence of any safety concerns. 
The results were made public and patients in the comparator aspirin arm were given the 
opportunity to receive apixaban.  
COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) was a 
three-arm trial comparing the combination of low-dose rivaroxaban with aspirin vs aspirin or 
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early for strong evidence of superior efficacy with the combined treatment, even though there 
was some opposite signal regarding safety, i.e. a marked excess in major bleeding events on 
rivaroxaban-plus-aspirin compared with aspirin-alone 16–18. Nonetheless, the executive 
committee of the trial considered that the net clinical benefit outcome of cardiovascular 
death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical 
organ was lower with rivaroxaban plus aspirin than with aspirin alone (HR 0.80; P<0.001) to 
justify the termination of the trial. However, whether this net benefit applies to all patients is 
open to debate. That is, are there patients at high risk of bleeding who should avoid such a 
combined treatment?        
RCTs on patients with peripheral artery disease (PAD) are manifold and incorporate 
interventional, physiotherapeutic (i.e. exercise) and pharmacotherapeutic (mainly 
antithrombotic) strategies 19.  A common problem is to motivate PAD patients to participate in 
these RCTs 20,21. This often leads either to premature termination due to poor recruitment 20 
or to stop even before study initiation. This might in part be prevented through amendments 
to the study protocol. Furthermore, PAD patients appear to be more interested in a specific 
treatment, rather than willing to be randomized 22. 
Altogether, this might be why PAD is rarely studied in a specific RCT, but rather included in a 
broader group of cardiovascular patients, with the main focus on cardiac patients. Thus, the 
specific treatment effect on PAD patients is mostly reflected in a subgroup analysis. We 
intend to pursue the topic of subgroup analyses in a further article currently under 
preparation. 
Notable exceptions are the EUCLID (Examining Use of Ticagrelor In PAD) 23 and the recently 
published VOYAGER PAD (Vascular Outcomes studY of ASA alonG with rivaroxaban in 
Endovascular or surgical limb Revascularization for Perpheral Artery Disease) trial 24, which 
exclusively studied symptomatic PAD patients for the prevention of future cardiovascular risks 
through antiplatelet agents (ticagrelor vs. clopidogrel 23) or anticoagulants (rivaroxaban plus 
aspirin vs. aspirin alone 24).  
Why EUCLID and VOYAGER succeeded is not self-evident. Similar RCTs faced difficulties 
which then led to their premature termination. One good example is the TI-PAD (Ticagrelor in 
Peripheral Artery Disease Endovascular Revascularization) trial 25 of antiplatelet monotherapy 
(i.e. ticagrelor 90 mg twice daily vs. aspirin 100 mg once daily) in patients with PAD. The 
rationale for TI-PAD was the lack of evidence regarding optimal antiplatelet therapy in 
endovascular treatment of PAD patients, unlike in cardiology. It was hypothesized that 
ticagrelor’s increased potency for platelet inhibition compared with aspirin would lead to 
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involved with 90% open within 4 months. However, study enrollment was lower than 
anticipated with 0.04 patients per site per month. The reasons for this were manifold: a 4-week 
washout period for concomitant medication, logistic difficulties related to multiple study visits 
over a short period of time. Also peak walking time being the major endpoint, required a 
treadmill test as an inclusion criterion but scheduling and performance was not possible for all 
eligible subjects at every study site. Most important, the antiplatelet monotherapy after 
intervention was not well received: dual antiplatelet therapy (DAPT) was simply favored over 
the required monotherapy in the protocol, despite its lack of justification 26. Despite appropriate 
protocol amendments, recruitment remained low over 13 months with 0.29 patients per site 
per months (less than half what was initially anticipated). Hence the trial was prematurely 
terminated. The rationale for the study of antiplatelet monotherapy after revascularization was 
more than justified but the protocol might have been too ambitious. The decision to terminate 
the trial was inevitable.   
     
Statistical considerations 
The decision to prematurely terminate a clinical trial depends on a multitude of factors, and 
besides advantages carries important risks (Figure 2). Whatsoever, it is always founded on 
statistical considerations. Statistical methods used in clinical trials are numerous, are laid out 
in the SAP (statistical analysis plan) of the trial and conform to the FDA and EMA guidelines 
of statistical principles of clinical trials. 
The statistical stopping guidelines will be trial-specific and should be documented in the 
DSMB charter. They should cover several potential reasons for terminating the trial i.e. for 
superiority, harm or futility as mentioned previously. The guidelines mainly focus on the 
primary endpoint for stopping. 
A clinical trial by definition compares interventions in a limited number of patients in order to 
extrapolate to the much larger number of subjects with the same condition who may 
subsequently benefit from the knowledge gained. This extrapolation is a challenge. When 
differences between treatment arms are found in the trial, they may be simply due to chance. 
The probability for such an error, the so-called type I or alpha error, is given as the p-value; 
conventionally, p-values <0.05 (indicating that the probability of a false positive result is below 
5%) are considered statistically significant.  
However, while the chances for a false positive result is low (as is reflected by a statistically 
significant, low p-value) for any single analysis, the chance to obtain a false positive result 
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increases with multiple tries. Hence, the naïve use of a p<0.05 in interim analyses with 
subsequent early termination of a trial would strongly increase the likelihood of false positive 
results and therefore is clearly not recommended. 
To overcome this problem statistical stopping boundaries may be used which require P-
values much smaller than 0.05 in order to stop a trial for efficacy 27,28. 
One such example is the O’Brien and Fleming rule 29. However, this requires a fixed number 
of planned interim-analyses. The Peto-Haybittle rule 30 is more flexible in that it specifies a 
fixed low p-vale such as <0.001 for the early termination of a trial, independently of the number 
of interim analyses. Alpha-Spending Functions (Lan, Kim and DeMets) can be used which 
allow flexibility when interim analyses happen, while controlling Type I error 31,32. 
The term “rule” is misleading, because these are not true rules, but rather objective guidelines 
to help data monitoring committees (DMCs) make recommendations based on the totality of 
evidence. Importantly, however, even when these rules are applied, early termination for 
efficacy biases results towards an exaggeration of the true treatment effect 33. This is due to 
the fact that overwhelming efficacy at one point may well reflect a random high, and 
subsequent longer observation (if allowed to happen) would on average show regression to 
the truth, i.e. a more moderate effect.  
It is generally recommended that stopping a trial for efficacy requires proof beyond reasonable 
doubt of a treatment benefit that will change clinical practice (e.g. the RECOVERY trial of 
dexamethasone for COVID 34). 
The “rules” mentioned above deal with the issue of stopping trials early for the unequivocal 
benefit of one intervention. But when evaluating whether to stop a trial early for safety 
problems or for lack of efficacy, other considerations become important. One statistical 
method used when stopping for futility is conditional power whereby one calculates the 
probability of achieveing a statistically significant treatment benefit at the end of the trial 
given the data so far. If this is unacceptably low one may consider stopping early for futility. 
However, with an early termination for lack of efficacy other advantages of the studied 
intervention may be lost and the value of the trial for potential future meta-analyses is 
decreased. 
Usually, for ethical reasons, somewhat weaker evidence is required to stop a trial because of 
potential harm of a new treatment. While one still has to be cautious in not over-reacting to 
potentially false safety signals, there is an ethical need to protect patients from being 
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early for efficacy, stopping a trial early for potential harm or for lack of efficacy cannot be solely 
based on statistical rules. The whole body of existing evidence will influence this decision. 
To further illustrate these issues some examples are given below. 
An adaption of the Peto stopping criteria were used in the EMPHASIS-HF (Eplerenone in 
Mild Patients Hospitalization and Survival Study in Heart Failure) trial, evaluating eplenerone 
against placebo in patients with chronic systolic heart failure and mild symptoms 35. Two 
interim analyses were planned: at the second one after 542 primary end points had accrued, 
the trial could be recommended to stop if it reached p < 0.001 for reduction of CV death and 
HF hospitalization. The trial was indeed stopped early due to such superiority after a median 
follow-up period of 21 months and the HF guidelines revised to include the effect of 
eplerenone. 
The COMPASS trial evaluated 27.395 patients with chronic coronary artery disease to 
rivaroxaban plus aspirin vs aspirin alone vs rivaroxaban alone 16. The trial was stopped after 
just 23 months on recommendation of the DSMB for superiority of rivaroxaban plus aspirin 
(P<0.0001). Rivaroxaban alone also showed marginally positive results (P<0.05) initially 
compared to aspirin alone. However, between stopping the trial and publication of the final 
data, the difference between rivaroxaban alone and aspirin alone had attenuated to non-
significance indicating some regression to the truth.  
In the GALILEO trial 1520 patients were randomized to Rivaroxaban 10mg plus aspirin vs 
aspirin plus clopidogrel after transcatheter aortic-valve replacement (TAVR) 36. In March 
2018 the DSMB noted excess of bleeds in the rivaroxaban arm and a negative trend for the 
primary end point, death or thrombotic event. In August 2018 there was firm evidence that 
rivaroxaban resulted in an excess of death or any thrombotic event after TAVR as well as 
major bleeds and the trial was stopped early for safety reasons.  
The publication of a trial that stops early claiming superiority needs to recognize that less 
information is available than if the trial had continued to its originally intended conclusion. 
Specifically, a trial that stops early is prone to exaggerate treatment efficacy, and had it 
continued longer some regression to the truth might be expected. These issues indicate the 
need for interim results of a trial to demonstrate proof beyond reasonable doubt of treatment 
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Pharmaceutical companies and regulatory aspects  
The primary goal of pharmaceutical companies that invest in drug development is to achieve 
a label for the compound. A label is a marketing license indication issued by a Regulatory 
Agency - most importantly by the US Food and Drug Administration (FDA) or the European 
Medicines Agency (EMA) - preferably both - as a result of RCTs. A label allows marketing 
and advertisement of a drug, and thus profits ensue.  
To achieve success, big pharma companies organize work in several departments: typically, 
the Marketing Department, the Research and Development Department, the Clinical 
Operations Department and Regulatory Affairs. Hence, the Marketing Department sets the 
company goal of RCTs to evaluate medical need and consequent profitability. The Research 
and Development Department figures out the path to achieve the goal set by the Marketing 
Department and produces the trial protocol to do so, often in collaboration with independent 
clinical and statistical experts who may form a Trial Executive Committee. The Clinical 
Operations Department makes it possible to conduct the RCT on a practical level, i.e. 
organizes sites, site monitoring, database management etc.; and Regulatory Affairs 
assesses the outcome goals required for a label and interacts with FDA and EMA. 
The key aspects of stopping a trial prematurely are as discussed above efficacy, futility and 
harm. In general terms stopping a trial prematurely for efficacy and futility is based upon 
statistical considerations of predetermined significance. However, harm does not need to 
reach a conventional level of statistical significance, for a signal of harm to stop even an 
entire drug development program. An example of this was seen in the F7CARD-1610 trial in 
which recombinant Factor VIIa significantly decreased reoperation rate for bleeding following 
coronary artery bypass grafting (CABG), but also showed a trend of thromboembolic events 
in the active drug group. This stopped the development of recombinant Factor VIIa in critical 
bleeding, although the use of recombinant Factor VIIa to certain degree continues even 
today off-label 37. 
As for efficacy assessments, interim analysis plans may be allowed in pivotal registration 
RCTs under the aegis of an independent DSMB that has no other connections to the trial. It 
is essential that we have pre-defined statistical stopping guidelines with strict preservation of 
the overall type I error. 
From a regulatory point, it may not be acceptable to stop a trial early during its execution, 
even in spite of apparent convincing efficacy results, because of insufficient data on safety 
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be compared to stopping a football match at half time when the team you favor is ahead. 
Your team could or might still lose after completion of the second half. 
In any case, interim analyses without realistic objectives should be avoided during the course 
of the study. Primary efficacy data should be complemented by a demonstration of 
consistency of trial results. However, if a trial is to be terminated early as a result of an 
interim analysis it is always important to perform additional analyses on the final trial 
database including all patient follow up that did not contribute to the interim analysis, and 
independent adjudication of all primary endpoints. 
 
Conclusions 
Stopping a trial early is an important contemporary issue that is of interest to every 
cardiologist in order to interpret trial findings and to make a subsequent wise choice in 
therapeutic management. This particularly holds true for cardiovascular pharmacotherapy.  
To ensure that investigational treatments are as safe as possible for the participating 
individuals, DSMBs are a cornerstone of each trial. Their challenges are to interpret data 
correctly and look for evidence of efficacy, futility, or harm that becomes gradually evident 
along with accruing endpoints. The DSMB receives interim endpoint data usually in a semi-
blinded fashion (A vs B) but it is common practice for the DSMB to confidentially unblind the 
treatment code when necessary. 
With appropriate priority, reasons for stopping are evidence of efficacy, futility, or safety at 
interim analysis. The a priori selection of key endpoints with an emphasis on the pre-defined 
primary endpoint is mandatory. We strongly suggest relying on hard endpoints when 
considering efficacy or safety as a reason for termination; and not on findings that do not 
affect the prognosis of randomized subjects. These principles are underlined by multiple 
examples of lipid and antithrombotic trials in this article. 
Statistical considerations are the main basis for decisions by the DSMB. The principal 
methods and examples are outlined, with the recognition that all DSMB recommendations 
rest on their wise judgement based on the totality of evidence. 
 
Finally, we highlight regulatory aspects, shedding light on the differing and sometimes 
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interests should always be and mostly is the patient, taking into account the needs of both, 
patients in the trial and the larger population of future patients. 
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